Skip to main content
NCBI home page
Oncotarget logoLink to Oncotarget
. 2016 Nov 21;7(50):82104–82111. doi: 10.18632/oncotarget.13486

KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer

Yayi He 1, Paul A Bunn 2, Caicun Zhou 1, Dan Chan 2
PMCID: PMC5347678  PMID: 27893413

Abstract

Background

Nature killer (NK) cells are the immune system's first line of defense against both viral infections and tumors. Killer cell immunoglobulin-like receptors (KIRs) are associated with susceptibility to different types of cancers. We investigated KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression and their association with survival in non-small cell lung cancer (NSCLC).

Methods

The expression of KIR 2D (L1, L3, L4, S4) (BC032422/ ADQ31987/ NP_002246/ NP_036446, ABCAM) and KIR 3DL1 (AA 1-444, ABCAM) protein was assessed by immunohistochemistry (IHC) in 62 NSCLC patients.

Results

KIR 2D (L1, L3, L4, S4) and KIR 3DL1 were expressed both on NSCLC tumor cells and tumor infiltrating lymphocytes (TILs). Fourteen samples (22.6%) stained positive for KIR 2D (L1, L3, L4, S4) on the tumor cells, and 10 (16.1%) had positive expression on the TILs. Thirty-three samples (53.2%) stained positive for KIR 3DL1 on the tumor cells, and 31 (50.0%) had positive expression on the TILs. Patients with negative KIR 2D (L1, L3, L4, S4) expression on tumor cells or TILs had longer overall survival (OS) than patients who are KIR 2D (L1, L3, L4, S4) positive on tumor cells (40.70 weeks, 95% CI 24.76-56.65 vs. 7.10 weeks, 95% CI 0.00-19.38, P = 0.014) or TILs (40.70 weeks, 95% CI 24.05-57.35 vs. 3.90 weeks, 95% CI 0.00-9.17, P < 0.001). Likewise, longer OS was significantly correlated with negative expression of KIR 3DL1 on tumor cells (62.30 weeks, 95% CI 0.00-177.37 vs. 13.10 weeks, 95% CI 3.42-22.78, P < 0.001) or TILs (62.30 weeks, 95% CI 0.00-152.05 vs. 12.10 weeks, 95% CI 2.61-21.59, P < 0.001). Cox regression analysis showed that KIR 2D (L1, L3, L4, S4) on TILs was correlated with OS (P = 0.032, Odds Ratio 2.628 95%CI 1.089-6.340).

Conclusions

KIR 2D (L1, L3, L4, S4) and KIR 3DL1 expression was correlated with poor prognosis in NSCLC patients.

Keywords: KIR 2D (L1, L3, L4, S4); KIR 3DL1; NSCLC; Pathology Section

INTRODUCTION

Lung cancer is the primary cause of cancer death worldwide [1]. Chemotherapy, the standard first line therapy for advanced stage lung cancer, has a poor prognosis. Targeted therapy offers a more promising outcome in advanced non-small cell lung cancer (NSCLC) [2–4], but only patients who harbor driving mutations such as epidermal growth factor receptor (EGFR) potentially benefit [5, 6]. Immunotherapy can reverse tumor immune escape [7]. The inhibition of checkpoints, such as cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death ligand-1 (PD-L1) may produce more positive outcomes in lung cancer patients [8–13].

Human leukocyte antigen-I (HLA-I) and related killer cell immunoglobulin like receptors (KIRs) molecules are additional important molecules which could facilitate immune escape in cancer [14]. The KIRs are a family of receptors encoded by 14 polymorphic genes (KIR2DL1-5, KIR3DL1-3, KIR2DS1-5, KIR3DS1), seven of which are inhibitory and seven of which are activating [15]. Upregulating the specific KIR ligand either on the tumor or on the tumor infiltrating lymphocyte (TILs) could inhibit the anti-tumor immune reaction [16, 17]. Currently, little is understood about the mechanisms of KIRs in the lung cancer immune system.

In this study, we investigated KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in NSCLC patient tumor tissues by immunohistochemistry (IHC) and analyzed the correlation between KIR 2D (L1, L3, L4, S4), KIR 3DL1 and clinical pathological characteristics. We also conducted survival analysis in NSCLC patients.

RESULTS

Patient characteristics

NSCLC patient tissues were obtained from 62 patients from Dan Lab (University of Colorado) between January 2004 and November 2008. Among them, 30 (48.4%) were male and 32 (51.6%) were female. The median age was 63 years old. Thirteen (21.0%) were never smokers. Twelve patients (19.4%) were stage I or II, and 50 (80.6%) were stage III or IV. Forty-two patients (67.7%) had adenocarcinoma, and 16 (25.8%) had squamous cell carcinoma (SCC) (Table 1).

Table 1. Patient Characteristics (n = 62).

Characteristic Total
Age, median 63
<70, n (%) 44 (71.0%)
≥70, n (%) 18 (29.0%)
Gender,n (%)
Male 30 (48.4%)
Female 32 (51.6%)
Smoking status,n (%)
Non-smoker 13 (21.0%)
Smoker 49 (79.0%)
Lung cancer staging,n (%)
I-II 12 (19.4%)
III-IV 50 (80.6%)
Pathology,n (%)
SCC 16 (25.8%)
Adenocarcinoma 42 (67.7%)
NSCLC NOS/Mixed 4 (6.5%)
Open in a new tab

Characterization of KIR 2D (L1, L3, L4, S4) and KIR 3DL1 in lung cancer and their association with clinical pathological factors

KIR 2D (L1, L3, L4, S4) and KIR 3DL1 were expressed on both lung cancer cells and TILs. Fourteen samples (22.6%) stained positive for KIR 2D (L1, L3, L4, S4) on the tumor cells, and 10 (16.1%) had positive expression on the TILs. Thirty-three samples (53.2%) stained positive for KIR 3DL1 on the tumor cells, and 31 (50.0%) had positive expression on the TILs (Figure 1). High expression of KIR2D on tumor cells was significantly correlated with higher expression of KIR2D on TILs (P < 0.001), KIR 3DL1 on tumor cells (P = 0.001) and KIR 3DL1 on TILs (P < 0.001). The same relationship was also found between KIR2D on TILs and KIR 3DL1 on tumor cells (P = 0.001), KIR2D on TILs and KIR 3DL1 on TILs (P < 0.001), and KIR 3DL1 on tumor cells and KIR 3DL1 on TILs (P < 0.001) (Table S1). Neither the expression of KIR 2D (L1, L3, L4, S4) nor KIR 3DL1 correlated significantly with clinical pathological factors (Table S2).

Figure 1. IHC staining for KIR 2D (L1, L3, L4, S4) and KIR 3DL1 (20X).

Figure 1

Open in a new tab

Univariate and multivariate logistic analysis for predicting KIR 2D (L1, L3, L4, S4) and KIR 3DL1 expression

With the Cox regression model, no variable (age, gender, smoking history, lung cancer stage, pathology) predicted KIR 2D (L1, L3, L4, S4) or KIR 3DL1 expression on tumor cells or TILs (Table S3, S4).

Association between KIR 2D (L1, L3, L4, S4), KIR 3DL1 and OS in lung cancer patients

We found that patients who were KIR 2D (L1, L3, L4, S4) negative on tumor cells or TILs had longer OS than patients who are KIR 2D (L1, L3, L4, S4) positive on tumor cells (40.70 weeks, 95% CI 24.76-56.65 vs. 7.10 weeks, 95% CI 0.00-19.38, P = 0.014) or TILs (40.70 weeks, 95% CI 24.05-57.35 vs. 3.90 weeks, 95% CI 0.00-9.17, P < 0.001). Likewise, OS was significantly longer in patients not expressing KIR 3DL1 on tumor cells (62.30 weeks, 95% CI 0.00-177.37 vs. 13.10 weeks, 95% CI 3.42-22.78, P < 0.001) or TILs (62.30 weeks, 95% CI 0.00-152.05 vs. 12.10 weeks, 95% CI 2.61-21.59, P < 0.001) (Figure 2).

Figure 2. OS by KIR 2D (L1, L3, L4, S4) and KIR 3DL1.

Figure 2

Open in a new tab

Cox regression analysis of OS

Cox regression analysis showed that KIR 2D (L1, L3, L4, S4) on TILs was correlated with OS (P = 0.032, Odds Ratio 2.628 95%CI 1.089-6.340) (Table 2).

Table 2. COX regression analysis of OS.

Univariate Multivariate
Variables Odds Ratio 95% CI P Odds Ratio 95% CI P
Age (<70 vs. ≥70) 1.260 0.661-2.403 0.483
Gender (Female vs. Male) 0.837 0.465-1.506 0.552
Smoking status (Non-smoker vs. Smoker) 1.115 0.552-2.254 0.761
Stage (I-II vs. III-IV) 1.772 0.768-3.861 0.187
Pathology (NSCLC vs. SCLC) 0.677 0.354-1.293 0.237
KIR 2D on TILs (Negative vs. Positive) 2.219 1.151-4.277 0.017 1.020 0.463-2.246 0.961
KIR 2D on tumor cells (Negative vs. Positive) 4.273 1.976-9.239 <0.001 2.628 1.089-6.340 0.032
KIR 3DL1 on tumor cells (Negative vs. Positive) 3.107 1.625-5.939 0.001 1.426 0.185-10.985 0.734
KIR 3DL1 on TILs (Negative vs. Positive) 3.187 1.689-6.012 <0.001 1.857 0.244-14.133 0.550
Open in a new tab

DISCUSSION

In this study, we investigated KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in NSCLC tumor tissues and analyzed the correlation between KIR 2D (L1, L3, L4, S4), KIR 3DL1 and clinical pathological characteristics. We also conducted survival analysis in NSCLC patients.

Natural killer (NK) cells perform critical functions in the innate immune response. They both control viral infection and eliminate early stage cancer [18–21]. It remains unknown whether NK cells are directly anti metastatic or rather suppress antitumor immunity [22–24]. NK cells expressing NK cell receptors (NKRs) can release cytokines that activate antitumor effector cells to inhibit tumor cells. The receptors expressed by NK cells, CD94: NKG2 heterodimers and KIRs, could regulate NK cell activity [14].

It is possible that KIRs may modulate NK cell and T lymphocytes function, effecting cancer immune response. A correlation between KIR/HLA compound genotypes, viral infections, chronic inflammatory diseases, and autoimmune diseases has been reported [25]. In addition, KIR/HLA compound genotype is associated with susceptibility to leukemia, cervical neoplasia, melanoma, and Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) [18–21, 26–33]. It has been reported that the KIR 2DL2 phenotype frequency in leukemic patients was significantly higher than that in the general population. Moreover, almost all inhibitory KIRs were highly expressed in leukemia patients. KIR 3DL1 was expressed in almost all leukemia patients. In leukemia, KIR phenotype induced immune escape from NK cells [27]. KIRs also increased the risk of cervical intraepithelial neoplasia [28]. Combinations of KIRs and HLA affect the progression of cervical neoplasia. The presence of the activating receptor KIR 3DS1 resulted in increased risk of cervical neoplasia [29]. KIRs in EBV-associated NPC patients tend to more activating than those in healthy subjects [34]. Besson et al. found an association between Hodgkin's lymphoma and certain KIR alleles in strong linkage disequilibrium [31]. KIR 2DL2 receptors were expressed at higher levels in breast cancer patients relative to healthy controls. KIR 2DL2 in combination with the HLA-C heterozygote ligand (C1/C2) could increase susceptibility to breast cancer [19]. We detected KIR 2D (L1, L3, L4, S4) and KIR 3DL1 on both tumor cells and TILs in NSCLC, but found no correlation with clinical characteristics.

KIRs have already been reported on tumor-specific CTLs in malignant tumor [26, 35]. Functionally, those CTLs exhibited a low level of lytic activity against autologous tumor cells, which was dramatically increased upon KIR blockade with the specific antibody. In contrast to the constitutive and stable KIR expression in mature NK cells, the induction of a particular KIR repertoire in T cells under specific conditions might be one of the events leading to the lethargy of the immune effector cells [36]. Engagement of inhibitory KIR with the ubiquitous MHC-I molecules on the surface of most cells establishes NK cell tolerance toward normal cells. Upon interaction with MHC-I ligands on the target cells, KIR recruit protein tyrosine phosphatases to the plasma membrane, which counteract activating receptor signals to inhibit cytotoxicity and cytokine production [37]. Because inhibitory KIRs could regulate NK cell activation, therapeutic strategies which inhibit KIRs could combat cancer by improving NK cells' activity. KIR blockade may be a therapeutically viable option to boost NK cell mediated cytotoxicity responses in cancer patients [38]. We conducted a survival analysis and found that positive KIR 2D (L1, L3, L4, S4) and KIR 3DL1 expression on tumors and TILs was correlated with poor prognosis in NSCLC patients.

This study is limited in that it is retrospective and assessed a relatively small number of patients. We are going to expand our patient sample set and conduct a larger prospective study. Additionally, previous research had not established the cutoff for determination of positive KIR 2D (L1, L3, L4, S4) or KIR 3DL1 protein expression in lung cancer by IHC, nor was one provided by Abcam. Therefore, we decided the cutoff that we found best for predicting OS.

In this study, we analyzed the relationship between KIR 2D (L1, L3, L4, S4), KIR 3DL1 expression and clinical characteristics. We also examined the association between expression of KIR 2D (L1, L3, L4, S4), KIR 3DL1 and OS. We have demonstrated that KIR 2D (L1, L3, L4, S4) are KIR 3DL1 were highly expression on NSCLC tumor cells and TILs. Furthermore, positive KIR 2D (L1, L3, L4, S4) or KIR 3DL1 expression on tumor cells or TILs was correlated with poor prognosis in NSCLC patients. Additional studies are needed to analyze the mechanisms of the of KIR/HLA interactions that affect NK cells in lung cancer.

MATERIALS AND METHODS

Patients

Primary tumor specimens were obtained from 62 NSCLC patients from Dan Lab (University of Colorado) between January 2004 and November 2008. All patients were newly diagnosed with NSCLC. The patients had not undergone radiation or chemotherapy before the biopsy. Lung cancer stages were categorized by the 7th edition International Association for the Study of Lung Cancer (IASLC) TNM staging system. The protocol was approved by the Shanghai Pulmonary Hospital, Tongji University. All participants were competent to provide their consent.

IHC for KIR 2D (L1, L3, L4, S4) and KIR 3DL1

Paraffin tissue sections were baked in drying oven at 60°C for 1 hour. Slides were labeled and put in a Benchmark XT® (Ventana Medical Systems, Inc) autostainer. After treating slides with standard cell conditioning 1 for 60 minutes, KIR antibodies (KIR 2DL1+KIR 2DL3+KIR 2DL4+KIR 2DS4, BC032422/ ADQ31987/ NP_002246/ NP_036446, 1:75, ABCAM) (KIR 3DL1, AA 1-444, 1:1500, ABCAM) were applied, and the slides were incubated at 37°C for 1 hour. UltraView DAB detection and amplification kit was used. Slides were counterstained with hematoxylin for 4 minutes then post-counterstained with bluing agent for 4 minutes. Slides were washed then dehydrated in 70% to 100% reagent alcohol and xylenes baths before application of coverslips. We used human tonsil as the positive control for KIR 2D (L1, L3, L4, S4) and KIR 3DL1.

Determination of KIR 2D (L1, L3, L4, S4) and KIR 3DL1 IHC cutoff

All IHC results were independently checked by two pathologists. Staining was evaluated using the H score system [39]. We defined KIR 2D (L1, L3, L4, S4) positivity as an H score greater than 200 for tumor cells and greater than 210 for TILs, respectively. We chose to define KIR 3DL1 positivity on tumor cells and TILs as greater than 200 because that cut off best predicted OS.

Statistical Analysis

We performed statistical analysis by SPSS statistical software package (version 17.0; SPSS, Inc.; Chicago, IL). Chi-square tests were used to analyze correlation between KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression and clinical pathological variables. The odds ratios for positive KIR 2D (L1, L3, L4, S4) and KIR 3DL1 expression were calculated by a logistic regression model for factors including age, gender, smoking status, lung cancer stage and pathology. The survival curves were estimated by the Kaplan-Meier method. Univariate and multivariate analysis was performed using the Cox regression model to investigate the relationships between the correlative factors of age, gender, smoking status, pathology, lung cancer stage, KIR 2D (L1, L3, L4, S4) on tumor cells and TILs, KIR 3DL1 on tumor cells and TILs and OS. All statistics were 2-sided and statistical significance was defined as P<0.05.

SUPPLEMENTARY MATERIALS

Acknowledgments

This project was supported by Young Program of Shanghai Health Bureau.

Footnotes

CONFLICTS OF INTEREST

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

REFERENCES

  • 1.Chen W, Zheng R, Zhang S, Zou X, Zhao P, He J. Lung cancer incidence and mortality in China, 2009. Thoracic Cancer. 2013;4(2):102–108. doi: 10.1111/1759-7714.12025. [DOI] [PubMed] [Google Scholar]
  • 2.Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, Rodriguez JA, Janne P, Oulid-Aissa D, Soria JC. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res. 2006;12(20 Pt 1):6049–6055. doi: 10.1158/1078-0432.CCR-06-0260. [DOI] [PubMed] [Google Scholar]
  • 3.Cameron L, Solomon B. New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer. Curr Treat Options Oncol. 2015;16(10):49. doi: 10.1007/s11864-015-0367-z. [DOI] [PubMed] [Google Scholar]
  • 4.Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) Ann Oncol. 2015;26(9):1877–1883. doi: 10.1093/annonc/mdv276. [DOI] [PubMed] [Google Scholar]
  • 5.He Y, Li S, Ren S, Cai W, Li X, Zhao C, Li J, Chen X, Gao G, Li W, Zhou F, Zhou C. Impact of family history of cancer on the incidence of mutation in epidermal growth factor receptor gene in non-small cell lung cancer patients. Lung Cancer. 2013;81(2):162–166. doi: 10.1016/j.lungcan.2013.05.004. [DOI] [PubMed] [Google Scholar]
  • 6.He Y, Wang Y, Boyle T, Ren S, Chan D, Rivard C, Li X, Li J, Zhou C, Hirsch FR. Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma. Med Sci Monit. 2016;22:276–283. doi: 10.12659/MSM.896607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342(6165):1432–1433. doi: 10.1126/science.342.6165.1432. [DOI] [PubMed] [Google Scholar]
  • 8.Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365–1369. doi: 10.1038/70932. [DOI] [PubMed] [Google Scholar]
  • 9.Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800. doi: 10.1038/nm730. [DOI] [PubMed] [Google Scholar]
  • 10.Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239–245. doi: 10.1038/ni1443. [DOI] [PubMed] [Google Scholar]
  • 11.Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–3175. doi: 10.1200/JCO.2009.26.7609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. doi: 10.1056/NEJMoa1200694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi: 10.1056/NEJMoa1200690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Urosevic M, Trojan A, Dummer R. HLA-G and its KIR ligands in cancer--another enigma yet to be solved? J Pathol. 2002;196(3):252–253. doi: 10.1002/path.1057. [DOI] [PubMed] [Google Scholar]
  • 15.Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002;20:217–251. doi: 10.1146/annurev.immunol.20.092501.134942. [DOI] [PubMed] [Google Scholar]
  • 16.Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, Stahel RA, Dummer R, Trojan A. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol. 2001;159(3):817–824. doi: 10.1016/S0002-9440(10)61756-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood. 2002;99(2):609–617. doi: 10.1182/blood.v99.2.609. [DOI] [PubMed] [Google Scholar]
  • 18.Martin MP, Borecki IB, Zhang Z, Nguyen L, Ma D, Gao X, Qi Y, Carrington M, Rader JS. HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer. Immunogenetics. 2010;62(11-12):761–765. doi: 10.1007/s00251-010-0477-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Jobim MR, Jobim M, Salim PH, Portela P, Jobim LF, Leistner-Segal S, Bittelbrunn AC, Menke CH, Biazus JV, Roesler R, Schwartsmann G. Analysis of KIR gene frequencies and HLA class I genotypes in breast cancer and control group. Hum Immunol. 2013;74(9):1130–1133. doi: 10.1016/j.humimm.2013.06.021. [DOI] [PubMed] [Google Scholar]
  • 20.De Re V, Caggiari L, De Zorzi M, Talamini R, Racanelli V, Buonadonna A, Zagonel V, Cecchin E, Innocenti F, Toffoli G, DA M. Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. PLoS One. 2014;9(1):e84940. doi: 10.1371/journal.pone.0084940. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Kim HJ, Choi HB, Jang JP, Baek IC, Choi EJ, Park M, Kim TG, Oh ST. HLA-Cw polypmorphism and killer cell immunoglobulin-like receptor (KIR) gene analysis in Korean colorectal cancer patients. Int J Surg. 2014;12(8):815–820. doi: 10.1016/j.ijsu.2014.06.012. [DOI] [PubMed] [Google Scholar]
  • 22.Baxter AG, Smyth MJ. The role of NK cells in autoimmune disease. Autoimmunity. 2002;35(1):1–14. doi: 10.1080/08916930290005864. [DOI] [PubMed] [Google Scholar]
  • 23.Jie HB, Sarvetnick N. The role of NK cells and NK cell receptors in autoimmune disease. Autoimmunity. 2004;37(2):147–153. doi: 10.1080/0891693042000196174. [DOI] [PubMed] [Google Scholar]
  • 24.Tian Z, Gershwin ME, Zhang C. Regulatory NK cells in autoimmune disease. J Autoimmun. 2012;39(3):206–215. doi: 10.1016/j.jaut.2012.05.006. [DOI] [PubMed] [Google Scholar]
  • 25.Carrington M, Martin MP. The impact of variation at the KIR gene cluster on human disease. Curr Top Microbiol Immunol. 2006;298:225–257. doi: 10.1007/3-540-27743-9_12. [DOI] [PubMed] [Google Scholar]
  • 26.Guerra N, Guillard M, Angevin E, Echchakir H, Escudier B, Moretta A, Chouaib S, Caignard A. Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas. Blood. 2000;95(9):2883–2889. [PubMed] [Google Scholar]
  • 27.Verheyden S, Bernier M, Demanet C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia. 2004;18(12):2002–2007. doi: 10.1038/sj.leu.2403525. [DOI] [PubMed] [Google Scholar]
  • 28.Arnheim L, Dillner J, Sanjeevi CB. A population-based cohort study of KIR genes and genotypes in relation to cervical intraepithelial neoplasia. Tissue Antigens. 2005;65(3):252–259. doi: 10.1111/j.1399-0039.2005.00359.x. [DOI] [PubMed] [Google Scholar]
  • 29.Carrington M, Wang S, Martin MP, Gao X, Schiffman M, Cheng J, Herrero R, Rodriguez AC, Kurman R, Mortel R, Schwartz P, Glass A, Hildesheim A. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med. 2005;201(7):1069–1075. doi: 10.1084/jem.20042158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Naumova E, Mihaylova A, Stoitchkov K, Ivanova M, Quin L, Toneva M. Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals. Cancer Immunol Immunother. 2005;54(2):172–178. doi: 10.1007/s00262-004-0575-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Besson C, Roetynck S, Williams F, Orsi L, Amiel C, Lependeven C, Antoni G, Hermine O, Brice P, Ferme C, Carde P, Canioni D, Briere J, Raphael M, Nicolas JC, Clavel J, et al. Association of killer cell immunoglobulin-like receptor genes with Hodgkin's lymphoma in a familial study. PLoS One. 2007;2(5):e406. doi: 10.1371/journal.pone.0000406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Portela P, Jobim LF, Salim PH, Koff WJ, Wilson TJ, Jobim MR, Schwartsmann G, Roesler R, Jobim M. Analysis of KIR gene frequencies and HLA class I genotypes in prostate cancer and control group. Int J Immunogenet. 2012;39(5):423–428. doi: 10.1111/j.1744-313X.2012.01115.x. [DOI] [PubMed] [Google Scholar]
  • 33.Vineretsky KA, Karagas MR, Christensen BC, Kuriger-Laber JK, Perry AE, Storm CA, Nelson HH. Skin Cancer Risk Is Modified by KIR/HLA Interactions That Influence the Activation of Natural Killer Immune Cells. Cancer Res. 2016;76(2):370–376. doi: 10.1158/0008-5472.CAN-15-0547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Butsch Kovacic M, Martin M, Gao X, Fuksenko T, Chen CJ, Cheng YJ, Chen JY, Apple R, Hildesheim A, Carrington M. Variation of the killer cell immunoglobulin-like receptors and HLA-C genes in nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2005;14(11 Pt 1):2673–2677. doi: 10.1158/1055-9965.EPI-05-0229. [DOI] [PubMed] [Google Scholar]
  • 35.Gati A, Guerra N, Giron-Michel J, Azzarone B, Angevin E, Moretta A, Chouaib S, Caignard A. Tumor cells regulate the lytic activity of tumor-specific cytotoxic t lymphocytes by modulating the inhibitory natural killer receptor function. Cancer Res. 2001;61(8):3240–3244. [PubMed] [Google Scholar]
  • 36.Mingari MC, Moretta A, Moretta L. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol Today. 1998;19(4):153–157. doi: 10.1016/s0167-5699(97)01236-x. [DOI] [PubMed] [Google Scholar]
  • 37.Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR) Cancer Biol Ther. 2009;8(23):2211–2220. doi: 10.4161/cbt.8.23.10455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nature reviews Immunology. 2007;7(5):329–339. doi: 10.1038/nri2073. [DOI] [PubMed] [Google Scholar]
  • 39.Hirsch FR, Varella-Garcia M, Bunn PA, Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21(20):3798–3807. doi: 10.1200/JCO.2003.11.069. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

oncotarget-07-82104-s001.pdf (532.6KB, pdf)

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES